The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index; 72 of the 132 sources its claims cite were checked for support.
Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial
Open accessPublished version of a preprint
Abstract
Background: A significant number of individuals with alcohol use disorder remain unresponsive to currently available treatments, which calls for the development of new alternatives. In parallel, psilocybin-assisted therapy for alcohol use disorder has recently yielded promising preliminary results. Building on extant findings, the proposed study is set to evaluate the feasibility and preliminary clinical efficacy of psilocybin-assisted therapy when incorporated as an auxiliary intervention during inpatient rehabilitation for severe alcohol use disorder. Moreover, it intends to pinpoint the modifications in the two core neurocognitive systems underscored by dual-process models of addiction. Methods: In this double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial, 62 participants aged 21–64 years will be enrolled to undergo psilocybin-assisted therapy as part of a 4-week inpatient rehabilitation for severe alcohol use disorder. The experimental group will receive a high dose of psilocybin (30 mg), whereas the control group will receive an active placebo dose of psilocybin (5 mg), both within the context of a brief standardized psychotherapeutic intervention drawing from key elements of acceptance and commitment therapy. The primary clinical outcome is the between-group difference regarding the change in percentage of heavy drinking days from baseline to four weeks posthospital discharge, while safety and feasibility metrics will also be reported as primary outcomes. Key secondary assessments include between-group differences in terms of changes in (1) drinking behavior parameters up to six months posthospital discharge, (2) symptoms of depression, anxiety, trauma, and global functioning, (3) neuroplasticity and key neurocognitive mechanisms associated with addiction, and (4) psychological processes and alcohol-related parameters. Discussion: The discussion outlines issues that might arise from our design. Trial registration: EudraCT 2022-002369-14 and NCT06160232. © 2024, The Author(s).
Overview
CoChat Summary
## TL;DR
This paper is a protocol for a double-blind, randomized, placebo-controlled phase II superiority trial testing whether a single 30 mg dose of psilocybin, delivered with brief psychotherapy during inpatient rehabilitation, improves outcomes for severe alcohol use disorder (sAUD) versus a 5 mg active placebo. It also aims to measure feasibility, safety, blinding, and proposed neurocognitive and psychological mechanisms over a 7-month follow-up.
## Key findings
- The trial will enroll 62 participants aged 21–64 years with severe alcohol use disorder and randomize them 1:1 to 30 mg psilocybin vs 5 mg psilocybin (active placebo) during a 4-week inpatient rehabilitation program.
- The primary clinical outcome is the between-group difference in change in percentage of heavy drinking days from baseline to 4 weeks posthospital discharge; the paper states the sample-size calculation targeted n = 46 for this analysis and increased to n = 62 to allow for 25% attrition.
- The study will also report feasibility and safety as primary outcomes, including inclusion and retention rates and systematic adverse-event recording.
- The protocol’s hypotheses are that the high-dose group will have a greater reduction in heavy drinking days and better alcohol-related, psychological, and neurocognitive outcomes, while serious adverse reactions will not differ between groups.
## Methods
- Design: Monocentric, double-blind, randomized, placebo-controlled, 1:1 parallel-group, 7-month phase II superiority trial at the Psychiatry Department of Brugmann University Hospital.
- Sample/data: 62 participants with sAUD, ages 21–64, undergoing a 4-week alcohol detoxification program; the intervention is 30 mg psilocybin vs 5 mg psilocybin active placebo, each embedded in a brief standardized psychotherapy protocol drawing from ACT.
- Analysis: The plan is to use intention-to-treat analyses for clinical outcomes, mixed-model ANOVA for continuous outcomes, general linear mixed models for time series with missing data, and chi-squared or Fisher’s exact tests for adverse events; mediation analyses will examine whether mechanistic variables explain treatment effects.
## Limitations
- The paper states that using a low yet psychoactive 5 mg active placebo may still produce therapeutic effects and may fail to maintain blinding; it also may reduce between-group effect sizes.
- The authors state that the trial’s strict inclusion and exclusion criteria limit how representative the sample can be, even though the study is intended to be pragmatic.
- Evident from the protocol: this is a protocol paper, so it reports planned outcomes and methods rather than trial results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
48 Valid · 3 Not valid · 25 Not checked · 15 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Several studies established a causal role for reduced prefrontal metabotropic glutamate receptor 2 (mGluR2) function in craving and relapse responses in preclinical models of alcohol dependence [48–52].”
§ Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial > Background > Psilocybin-assisted therapy for severe alcohol use disorder: potential mechanisms of action
What the sources say
- Supportedcites [48] Meinhardt MW, Pfarr S, Fouquet G, Rohleder C, Meinhardt ML, Barroso-Flores J, et al. Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. Sci Adv. 2021. https://doi.org/10.1126/sciadv.abh2399. source
The Results section reports that reducing infralimbic prefrontal mGluR2 increased cue-induced reinstatement of alcohol seeking in rats, while restoring mGluR2 in alcohol-dependent rats reduced it. The Discussion describes the mGluR2 deficit as necessary and sufficient for increased craving. This paper supports the claim as one of the cited preclinical studies; its knockdown experiment used nondependent rats, alongside a reported experiment in alcohol-dependent rats. (LLM, conf=0.92)
- Partly supportedcites [49] Augier E, Dulman RS, Rauffenbart C, Augier G, Cross AJ, Heilig M. The mGluR2 positive allosteric modulator, AZD8529, and Cue-Induced Relapse to Alcohol seeking in rats. Neuropsychopharmacology. 2016. https://doi.org/10.1038/npp.2016.107. sourceExperimental — accuracy not yet measured
The Results (page unavailable) report that the mGluR2 modulator AZD8529 blocked cue-induced reinstatement of alcohol seeking in rats. The Discussion (page unavailable) also describes a prefrontal mGluR2 deficit in postdependent rats whose targeted rescue restored control over seeking, but attributes that experiment to Meinhardt et al. (2013). This paper does not itself establish that reduced prefrontal mGluR2 function causes craving and relapse responses in alcohol-dependent rats; its AZD8529 experiment tested a systemic treatment. (LLM, conf=0.84)
- Partly supportedcites [50] Caprioli D, Justinova Z, Venniro M, Shaham Y. Effect of Novel Allosteric modulators of Metabotropic Glutamate receptors on Drug Self-administration and relapse: a review of Preclinical studies and their clinical implications. Biol Psychiatry. 2018. https://doi.org/10.1016/j.biopsych.2017.08.018. sourceExperimental — accuracy not yet measured
The Group II metabotropic glutamate receptors > Reinstatement section (page unavailable) reports that an mGluR2 modulator reduced cue-induced alcohol seeking in rats, but not in rats lacking functional mGluR2, supporting a causal role for mGluR2 in that relapse response. It does not establish that reduced *prefrontal* mGluR2 function causes craving and relapse in models of alcohol dependence; its alcohol finding concerns cue-induced reinstatement, not craving broadly. (LLM, conf=0.85)
- Partly supportedcites [51] Holmes A, Spanagel R, Krystal JH. Glutamatergic targets for new alcohol medications. Psychopharmacology. 2013. https://doi.org/10.1007/s00213-013-3226-2. sourceExperimental — accuracy not yet measured
The Metabotropic glutamate receptors section reports reduced prefrontal mGluR2 expression after chronic ethanol exposure and that restoring infralimbic mGluR2 in alcohol-exposed rats reduced cue-induced reinstatement. It also describes several studies of mGluR2/3 agonists and alcohol-seeking, but does not establish that several studies specifically demonstrated a causal role for reduced prefrontal mGluR2 function in both craving and relapse responses. Page numbers are not provided in the supplied passages. (LLM, conf=0.84)
- Disputedcites [52] Kufahl PR, Martin-Fardon R, Weiss F. Enhanced sensitivity to attenuation of conditioned reinstatement by the mGluR2/3 agonist LY379268 and increased functional activity of mGluR2/3 in rats with a history of ethanol dependence. Neuropsychopharmacology. 2011. https://doi.org/10.1038/npp.2011.174. sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports no significant difference in mGluR2/3 functional activity in the medial prefrontal cortex of ethanol-dependent versus control rats. It instead reports increased activity in the central amygdala and bed nucleus of the stria terminalis. Although the paper finds that an mGluR2/3 agonist reduces reinstatement of ethanol seeking, it does not establish a causal role for reduced prefrontal mGluR2 function. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These compounds present very low long-term toxicity [9, 10]”
§ Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial > Background > Background of the proposed study
What the sources say
- Supportedcites [9] Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008. https://doi.org/10.1177/0269881108093587. source
The Introduction identifies the paper’s classical hallucinogens as serotonergic psychedelics. The Physiological toxicity section says they have relatively low toxicity, with no demonstrated organ damage or neuropsychological deficits; the sections on prolonged psychosis and lasting perceptual abnormalities describe enduring adverse effects as rare, not absent. No page numbers were available in our copy. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [10] Tylš F, Páleníček T, Horáček J. Psilocybin–summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014. https://doi.org/10.1016/j.euroneuro.2013.12.006. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Preliminary preclinical evidence suggests that psychedelics’ psychoplastogenic properties [44] might directly counteract the hypofrontality observed in chronic alcohol exposure [48], thereby restoring the function of the reflective prefrontal system and its regulatory action on the reward system.”
§ Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial > Background > Psilocybin-assisted therapy for severe alcohol use disorder: potential mechanisms of action
What the sources say
- Supportedcites [44] Olson DE, Psychoplastogens. A Promising Class of plasticity-promoting neurotherapeutics. J Exp Neurosci. 2018. https://doi.org/10.1177/1179069518800508. source
Citation [44] is attached to psychedelics’ psychoplastogenic properties, not to the chronic-alcohol-exposure claim, which has a separate citation. The supplied passage labelled Abstract reports that psychedelic compounds promote dendritic branching and increase spine or synapse number in cortical neurons and in vivo. (LLM, conf=0.93)
- Supportedcites [48] Meinhardt MW, Pfarr S, Fouquet G, Rohleder C, Meinhardt ML, Barroso-Flores J, et al. Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. Sci Adv. 2021. https://doi.org/10.1126/sciadv.abh2399. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Across psychiatric diagnoses, PAT clinical trials have suggested a relationship between the quality of the acute psychedelic experience and clinical ameliorations [36, 53, 54].”
§ Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial > Background > Psilocybin-assisted therapy for severe alcohol use disorder: potential mechanisms of action
What the sources say
- Supportedcites [36] Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016. https://doi.org/10.1177/0269881116675512. source
The Discussion’s “Psycho-spiritual mechanisms” section reports that the intensity of mystical experiences significantly mediated reductions in anxiety and depression in this trial. It also describes correlations between mystical experiences and improved outcomes in trials for tobacco addiction and alcoholism, supporting the broader phrasing across diagnoses. Page numbers are not available in the supplied passages. (LLM, conf=0.92)
- Supportedcites [53] Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016. https://doi.org/10.1177/0269881116675513. source
The Results (Outcome measures) report that the quality of the acute experience, measured by mystical-experience scores, correlated with later depression and anxiety outcomes. The Discussion likewise describes a significant association between mystical-type experience during the session and therapeutic outcomes five weeks later. This trial supplies one example for the citing sentence’s collective claim about trials across diagnoses. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [54] Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015. https://doi.org/10.1177/0269881114565144. source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“are not associated with addiction [9, 11, 12]”
§ Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial > Background > Background of the proposed study
What the sources say
- Partly supportedcites [9] Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008. https://doi.org/10.1177/0269881108093587. sourceExperimental — accuracy not yet measured
The “Abuse and dependence” section says hallucinogens are not typically considered drugs of dependence and pose little risk of leaving research participants dependent. It also says they can be abused, so the unqualified statement that they are not associated with addiction overstates the paper’s more cautious conclusion. No page number is available in our copy. (LLM, conf=0.87)
- Supportedcites [11] Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the controlled substances Act. Neuropharmacology. 2018. https://doi.org/10.1016/j.neuropharm.2018.05.012. source
In Factor 5 (page unavailable), the paper says LSD- and psilocybin-type classic psychedelics are described as not addicting and distinguishes them from drugs that cause dependence or addiction. Factor 7 (page unavailable) also reports no documented withdrawal syndrome, while noting that tolerance can occur. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [12] van Amsterdam J, Opperhuizen A, van den Koeter M. Ranking the Harm of Alcohol, Tobacco and Illicit Drugs for the individual and the Population. Eur Addict Res. 2010. https://doi.org/10.1159/000317249. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
41 more claims · 24 with their cited sources checked
Create a free account to see all 91 claims and to verify the 4 references still open.
- It may state two separate claims as one. 22
- Probably not a substantial claim. 32
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032 · cited 1×
“…alcohol use disorders [18, 19, 102], we will assess changes in depression, anxiety, and trauma symptoms (*, ▲ ) using the Beck Depression Inventory (BDI; [103]), the State-Trait Anxiety Inventory (STAI; [104], trait subscale), and the International Trauma Questionnaire (ITQ; [105]), respectively.”
MethodDiagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Hirono, N., Mori, E., Ikejiri, Y., et al. (1997) · PubMed · Cited by 20,849
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,380
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363 · cited 1×
“Our protocol adheres to the SPIRIT guidelines (Standard Protocol Items: Recommendations for Interventional Trials [67]).”
Method
Research works printed but not linked: 1
- Spielberger CD. Manual for the state-trait anxiety inventory (self-Evaluation questionnaire). Palo Alto, CA: Consulting Psychologists Press; 1983.
Cited by
The Emergence of Psilocybin in Psychiatry and Neuroscience
Omidian, H., & Omidian, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040555 · Cited by 16
Pich, E. M., Tarnanas, I., Brigidi, P., & Collo, G. (2025) · Neurobiology of Stress · doi:10.1016/j.ynstr.2025.100713 · Cited by 21
Exploring the therapeutic potential of psychedelics in treating substance use disorders
Li, Y., Li, H., Wang, H., & Wang, X. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03168-w · Cited by 8
Keighley, E. E., Bedewy, D., Hamza, E. A., Nalla, S., & Moustafa, A. A. (2025) · Healthcare · doi:10.3390/healthcare13212668 · Cited by 7
Integration in classic psychedelic-assisted therapies for mental health conditions: A scoping review
Vucak, N., Bruno, R., Quealy, J. J., Casimaty, J. G., Rossell, S. L., Castle, D. J., & Acevedo, N. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100030
Metadata
- Authors
- Vanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., Mallet, L., Leys, C., & Noël, X.
- Affiliations
- Université Libre de Bruxelles (BE)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire Brugmann (BE)
- University of Geneva (CH)
- Corresponding author
- Vanderijst, Laetitia
- ORCID
- Venue
- BMC Psychiatry
- Published
- 2024-01-26
- Volume
- 24
- Issue
- 1
- Pages
- 77-77
- ISSN
- 1471-244X (ISSN-L)
- PMC
- PMC10821548
- OpenAlex
- W4391256257
- Cited by
- 13
- References
- 121
- Citations by year
- 2026: 6 · 2025: 7
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fonds De La Recherche Scientifique - FNRS (40010687)
- Fonds Iris-Recherche (2023-J1820690-232470)
- Brugmann Foundation (2022-10)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- psilocybin-assisted therapy, alcoholism, severe alcohol use disorder, neuroplasticity, heavy drinking days, anxiety and depressive symptoms, trauma symptoms, global functioning, acceptance and commitment therapy, active placebo, treatment safety and feasibility
- MeSH terms
- Equivalence Trials as Topic, Alcohol Drinking, Alcoholism, Double-Blind Method, Humans, Psilocybin, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase II as Topic, Acceptance and Commitment Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial. https://app.cochat.ai/papers/10.1186/s12888-024-05502-y
- The paper
- Vanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., Mallet, L., Leys, C., & Noël, X. (2024). Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial. BMC Psychiatry. https://doi.org/10.1186/s12888-024-05502-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.